Kura Oncology, Inc.
NASDAQ:KURA
Overview | Financials
Company Name | Kura Oncology, Inc. |
Symbol | KURA |
Currency | USD |
Price | 8.86 |
Market Cap | 688,986,382 |
Dividend Yield | 0% |
52-week-range | 8.75 - 24.17 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Troy Edward Wilson J.D., Ph.D. |
Website | https://kuraoncology.com |
An error occurred while fetching data.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD